157 related articles for article (PubMed ID: 35072775)
1. Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma.
Waldschmidt JM; Fruttiger SJ; Wider D; Jung J; Thomsen AR; Hartmann TN; Duyster J; Hug MJ; Azab KA; Jung M; Wäsch R; Engelhardt M
J Cancer Res Clin Oncol; 2022 May; 148(5):1045-1055. PubMed ID: 35072775
[TBL] [Abstract][Full Text] [Related]
2. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
4. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J; Koyama D; Mukai HY; Furukawa Y
Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
[TBL] [Abstract][Full Text] [Related]
5. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E
J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345
[TBL] [Abstract][Full Text] [Related]
6. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
7. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo evaluation of the effect of regulatory T cells on the anti-tumor activity of bortezomib in multiple myeloma.
Ercetin AP; Ozcan MA; Aktas S; Yuksel F; Solmaz SM; Sevindik GO; Katgi A; Piskin O; Undar B
Exp Hematol; 2016 Apr; 44(4):223-30. PubMed ID: 26774384
[TBL] [Abstract][Full Text] [Related]
9. A 3D-Bioprinted Multiple Myeloma Model.
Wu D; Wang Z; Li J; Song Y; Perez MEM; Wang Z; Cao X; Cao C; Maharjan S; Anderson KC; Chauhan D; Zhang YS
Adv Healthc Mater; 2022 Apr; 11(7):e2100884. PubMed ID: 34558232
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
11. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
[TBL] [Abstract][Full Text] [Related]
12. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
13. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.
Zhang G; Miao F; Xu J; Wang R
Bosn J Basic Med Sci; 2020 May; 20(2):209-217. PubMed ID: 31538911
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
[TBL] [Abstract][Full Text] [Related]
16. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.
Wang H; Xiao X; Li Z; Luo S; Hu L; Yi H; Xiang R; Zhu Y; Wang Y; Zhu L; Xiao L; Dai C; Aziz A; Yuan L; Cui Y; Li R; Gong F; Liu X; Liang L; Peng H; Zhou H; Liu J
Cancer Lett; 2022 Jul; 537():215647. PubMed ID: 35306105
[TBL] [Abstract][Full Text] [Related]
17. SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture.
Arhoma A; Chantry AD; Haywood-Small SL; Cross NA
Exp Cell Res; 2017 Nov; 360(2):226-235. PubMed ID: 28890292
[TBL] [Abstract][Full Text] [Related]
18. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
[TBL] [Abstract][Full Text] [Related]
19.
Terzi H; Altun A; Şencan M
Indian J Med Res; 2019 Dec; 150(6):630-634. PubMed ID: 32048627
[TBL] [Abstract][Full Text] [Related]
20. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
